EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Macular Sensitivity after Intravitreal Ranibizumab Injection for Macular Edema in Central Retinal Vein Occlusion: One versus Three Initial Monthly Injections

Erina Niidome, Hidetaka Noma, Kanako Yasuda, Kosei Yanagida, Akitomo Narimatsu, Masaki Asakage, Sho Watarai, Hiroshi Goto, Masahiko Shimura

Journal of Vascular Diseases · 2022

DOI: 10.3390/jvd1010006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Vascular Diseases, 2022. Verfasst von Erina Niidome und 8 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to compare the macular sensitivity after one initial intravitreal injection of an anti-vascular endothelial growth factor (VEGF) agent followed by pro re nata (PRN) dosing with that after three initial monthly injections followed by PRN dosing in patients with central retinal vein occlusion (CRVO) and macular edema.

Methods

We included 20 eyes of 20 patients with treatment-naïve macular edema in CRVO and followed them for 12 months after intravitreal ranibizumab injection (IRI). Before and 1, 3, 6, and 12 months after IRI, macular sensitivity within the central 1 mm, 3 mm, and 6 mm fields was measured with an MP3 microperimeter and best-corrected visual acuity (BCVA) was assessed. Eleven eyes received one initial IRI (1 + PRN group), and nine received three initial monthly IRIs (3 + PRN group). PRN injections were performed when fovea exudative changes were evident.

Results

Mean macular sensitivity within the central 1 mm, 3 mm, and 6 mm fields significantly improved from baseline to month 12 in all treated eyes. We found no significant differences in macular sensitivity in the central 1 mm, 3 mm, or 6 mm fields between the two groups at month 1, 3, 6, or 12. The choice of treatment regimen (1 + PRN or 3 + PRN) showed no association with either macular sensitivity in the central 1 mm, 3 mm, and 6 mm fields or BCVA at month 12.

Conclusions

These findings suggest that a 1 + PRN regimen improves macular sensitivity to a similar extent as a 3 + PRN regimen.

Zitieren

APA

Niidome, E., Noma, H., Yasuda, K., Yanagida, K., Narimatsu, A., Asakage, M., Watarai, S., Goto, H., & Shimura, M. (2022). Macular Sensitivity after Intravitreal Ranibizumab Injection for Macular Edema in Central Retinal Vein Occlusion: One versus Three Initial Monthly Injections. Journal of Vascular Diseases. https://doi.org/10.3390/jvd1010006

Vancouver

Niidome E, Noma H, Yasuda K, Yanagida K, Narimatsu A, Asakage M, et al. Macular Sensitivity after Intravitreal Ranibizumab Injection for Macular Edema in Central Retinal Vein Occlusion: One versus Three Initial Monthly Injections. Journal of Vascular Diseases. 2022. doi:10.3390/jvd1010006

BibTeX
@article{Niidome2022,
  author = {Niidome, Erina and Noma, Hidetaka and Yasuda, Kanako and Yanagida, Kosei and Narimatsu, Akitomo and Asakage, Masaki and Watarai, Sho and Goto, Hiroshi and Shimura, Masahiko},
  title = {Macular Sensitivity after Intravitreal Ranibizumab Injection for Macular Edema in Central Retinal Vein Occlusion: One versus Three Initial Monthly Injections},
  journal = {Journal of Vascular Diseases},
  year = {2022},
  doi = {10.3390/jvd1010006}
}
Kostenlos starten →